What does NextConsensus produce?

Medical-transition forecasts and evidence baselines. NextConsensus estimates the probability that named guideline bodies, regulators, and payers will take defined public actions by stated deadlines, grounded in an auditable public evidence record.

What makes this different from document monitoring?

Monitoring reports what has already been published. NextConsensus registers, before the outcome is known, the probability that a named guideline body, regulator, or payer takes a defined action by a date, with the rule that settles it, and scores each forecast against its baselines after the deadline passes.

We estimate the probability that a guideline, label, or coverage policy changes before your submission date.

Your team decides what to prepare, price, and prioritize while the decision is still open, not after it publishes. A single-claim evaluation is a fixed $15,000 and delivers in ten business days, and the same record can then cover every decision your portfolio is waiting on.

Built for market access, HEOR, regulatory, BD, and portfolio teams with a date already on the calendar.

Founded by Kanav Jain, who built products at Epic, Doximity, Transcarent, and CancerCompass. About the company

On the record

The next deadlines

Registered estimates of a named body acting by a stated date, from the 2026-10-06 registry snapshot.

FF-007FDA Bepirovirsen · hepatitis B approval Oct 26, 2026Unresolved FF-016NICE Epcoritamab combination · guidance publication Oct 28, 2026Unresolved FF-010FDA INO-3107 · papillomatosis approval Oct 30, 2026Unresolved

Deadlines by week, Oct–Dec 2026 · 25 of 29 registered

Unresolved
Resolved
Not scored
Expired

29 registered · 29 unresolved · 0 resolved

By class: FDA action by goal date (14), NICE guidance by scheduled date (11), NCCN guideline reclassification (2), FDA label revision (2).

Read all 29 registered forecasts Add every deadline to your calendar

You name: One claim: a drug and its indication, or the coverage restriction you are up against.
You get: The probability for your date, the dated evidence baseline, and where the evidence has stalled.
In time for: A P&T meeting. An HTA submission. A label negotiation. A deal closing.

The claim was fine when you filed it

A market access team builds a payer deck in March. The claim holds up: the trial showed benefit, the label carries the indication, the guideline recommends use. In August a new readout narrows the guideline, and the label follows. The deck is still in circulation.

The full case, and the check to run before your date

What a probability is for

It feeds decisions with dates of their own: what to put behind an asset before a guideline listing, what to have ready for a coverage review, what to pay in diligence. Decide which branch to build now, and keep the other written down.

10 of 29 registered estimates sit 15 points or more from their base rate. They are scored apart from the rest of their class.

The 3 furthest from their base rate are below.

FF-011FDABase rate 70% · 55 points below Ivonescimab · post-TKI NSCLC approval Nov 14, 2026Unresolved FF-009FDABase rate 85% · 50 points below IGALMI · at-home supplement approval Nov 14, 2026Unresolved FF-020NICEBase rate 50% · 45 points below Orforglipron · guidance publication Nov 18, 2026Unresolved

If the institution acts

Evidence preparation before a P&T or HTA deadline

What market access, HEOR, and medical affairs teams can prepare twelve, six, or three months before a committee or submission deadline.

If it does not

When a guideline, label, or coverage change is delayed

Distinguish missing evidence, procedural delay, a different action, and an outcome after the deadline when an institutional change does not arrive.

Both branches are also written out by team and horizon in the planning guides.

The record so far

Registered: 29
Resolved: 0
Awaiting registration: 21

Phase 1 of the record · registered before outcomes · registry snapshot 2026-10-06 · outcomes pending

How a forecast is scored